๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Denosumab decreases bone turnover in advanced cancer

Book ID
120851125
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2006
Weight
120 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Denosumab and changes in bone turnover m
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer
โœ Matthew R Smith; Fred Saad; Blair Egerdie; Paul Sieber; Teuvo LJ Tammela; Benjam ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› American Society for Bone and Mineral Research ๐ŸŒ English โš– 127 KB

## Abstract Androgen deprivation therapy (ADT) for prostate cancer increases fracture risk, decreases bone mineral density, and increases bone turnover markers (BTMs) including serum type 1 Cโ€telopeptide (sCTX), tartrateโ€resistant alkaline phosphatase 5b (TRAPโ€5b), and procollagenโ€1 Nโ€terminal telo

Effects of denosumab on bone turnover ma
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
โœ Richard Eastell; Claus Christiansen; Andreas Grauer; Stepan Kutilek; Cesar Liban ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› American Society for Bone and Mineral Research ๐ŸŒ English โš– 272 KB ๐Ÿ‘ 1 views

## Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the time course and determinants of bone turnover marker (BTM) response during denosumab treatment, the percentage of denosumabโ€treat